Full Press Release Details
Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial.
IMMP
Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial
Key Takeaway: Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)